Cipla share price declined 2 percent after the United States Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI). At 09:29am, Cipla was quoting ...

Cipla: The pharma player has informed the exchanges that its manufacturing facility in Bengaluru's Virgonagar has received a Voluntary Action Indicated status from the USFDA. VA Tech Wabag ...

Shares of Cipla Ltd. fell as much as 2% on Monday after the Mumbai-based drug manufacturer informed the exchanges that its manufacturing facility in Bengaluru's Virgonagar has received a Voluntary ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...

The biosimilar of IL-6 inhibitor tocilizumab, called Tyenne (formerly MSB11456), has been approved for the same indications as Roche’s brand, including rheumatoid arthritis, systemic juvenile ...

Solarium Green Energy IPO: Solarium Green Energy’s ₹105.04 crore SME IPO opens on February 6, with shares priced at ₹181-191. Funds will support working capital and corporate expenses. Listing on BSE ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

The Listing Page of Cipla Ltd. presents the Incorporation Date, Public Issue Date, Book Closure dates, Face Value, Key Listing information, Indices it is a part of, and the Exchanges where the company ...

We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using ...